STEM CELL THERAPY FOR PARKINSON’S DISEASE: A REVIEW
{ DOWNLOAD AS PDF }
ABOUT AUTHORS
Vipul Gandhi*, Sushil Burle, Satish Kosalge
Hi-Tech College of Pharmacy Chandrapur
Padoli Phata, Nagpur Highway, Morwa, Chandrapur-442406.
*vipul96gandhi@gmail.com
ABSTRACT
Some of the problems with Un productive relaxing treatments and insufficient repair aptitude in the central nervous system are most troubling problems for few neurological diseases. Providentially, the development of clinically relevant populations of stem cells has provided an opportunity to overcome the failure of endogenous repair systems and substitute new cells into the injured brain. However, there are still several existing difficulties in interpreting into clinical application. In this review, we mainly focus on the stem cell based therapies for Parkinson’s disease and discuss the possible advantages and drawbacks. We hope this review may provide suggestions for viable policies to overcome the current technical and biological issues relatedto the application of stem cells in Parkinson’s disease (Fu et al., 2015).

Syngene International is one of India’s premier contract research and manufacturing organizations in providing customized service. Our services encompasses all across discovery chain: early stage discovery, process development, cGMP manufacturing and formulation development both in the small molecule and novel biologics area. Based in Bangalore, Karnataka, the Company is situated in a 90 acre Special Economic Zone with over 100000 sq. mt of built up facilities. The state-of-the-art research facilities have been qualified by various pharmaceutical majors & regulatory agencies and has received various certifications including ISO 9001: 2008, ISO 14001:2004, OHSAS 18001:2007, GLP and AAALAC.

